2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
22
Neoplasms
20
Leukemia, Myeloid, Acute
10
Ovarian Neoplasms
7
Neoplasm Metastasis
7
Lymphoma
7
Lung Neoplasms
7
Hematologic Neoplasms
6
Glioblastoma
6
Colorectal Neoplasms
6
Prostatic Neoplasms
5
Pancreatic Neoplasms
5
Multiple Myeloma
5
Leukemia
5
Fatigue
5
Stomach Neoplasms
4
Depression
4
Carcinoma, Non-Small-Cell Lung
4
Vulvar Neoplasms
3
Uterine Cervical Neoplasms
3
Urinary Bladder Neoplasms
3
Triple Negative Breast Neoplasms
3
Sarcoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Pain
3
Myelodysplastic Syndromes
3
Motor Activity
3
Melanoma
3
Carcinoma, Hepatocellular
3
Anxiety Disorders
3
Interventions
Nivolumab
20
Ipilimumab
10
Surveys and Questionnaires
7
Paclitaxel
7
linrodostat
6
Standard of Care
6
Sirolimus
5
Gemcitabine
5
Bevacizumab
5
temsirolimus
4
relatlimab
4
Pemetrexed
4
Interviews as Topic
4
Docetaxel
4
Carboplatin
4
ARRY-334543
4
Vorinostat
3
Erlotinib Hydrochloride
3
Dasatinib
3
Cetuximab
3
regorafenib
2
olaparib
2
apatinib
2
anlotinib
2
abemaciclib
2
Trastuzumab
2
Sunitinib
2
Sorafenib
2
Olanzapine
2
N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Cancer
×
Palliative Care
×
Clear all
NCT01444157
2014-07-18
FamCope
Bispebjerg Hospital
Phase 3
Completed
700 enrolled